HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical-stage biotech driving a pipeline of transformative immunotherapies. The company is targeting the root cause of disease through its unique Drug Intelligence Science (DIS®) platform, which enables deep understanding of cellular pathology across various diseases through proprietary single cell technology and AI/ML analytics. This platform is deployed in target discovery, antibody selection, and predictive biomarker identification. The company started in 2017 with the goal of leveraging deep immune modulation expertise and cutting edge single cell technology to deliver transformative medicines to patients. Its vision is to unlock the curative powers of the immune system for each and every patient, and its mission is to build an industry leading biotech to deliver transformative immunotherapies.

HiFiBiO Therapeutics started in 2017 with the goal of leveraging deep immune modulation expertise and cutting edge single cell technology to deliver transformative medicines to patients. The company is a clinical-stage biotech driving a pipeline of transformative immunotherapies. It has completed 4 Phase I Dose Escalation Trials, filed and cleared 6 INDs, discovered 8 Clinical Candidates, and established 12+ Partnerships. Fred Dom is one of the original founders and Chief Executive Officer of HiFiBiO Therapeutics.

Clinical-stage biotech pioneering curative immunotherapies for patients with high unmet medical needs.

• EMUNKITUG (HFB200301)

• HFB200603

• NUVUSTOTUG (HFB301001)

• HFB200604

• HFB3024

1. 1Home - HiFiBiO Therapeuticshifibio.com
2. 2Company Overview - HiFiBio Therapeuticshifibio.com
3. 3Contact - HiFiBio Therapeuticshifibio.com
4. 4Leadership - HiFiBio Therapeuticshifibio.com
5. 5HiFiBiO Therapeutics (United States)wikidata.org